Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes
- Hee Kyung Ahn†1,
- Yeon Hee Park†1,
- Su Jin Lee1,
- Silvia Park1,
- Chi Hoon Maeng1,
- Won Park2,
- Doo Ho Choi2,
- Seung Jae Hur2,
- Jin Seok Ahn1 and
- Young-Hyuck Im1Email author
© Ahn et al.; licensee Springer. 2013
Received: 22 January 2013
Accepted: 24 January 2013
Published: 28 March 2013
The aims of the present study were to investigate how breast cancer (BC) subtypes and treatment affect time to brain metastasis (TTBM). We retrospectively investigated 189 consecutive patients who were diagnosed with brain metastasis (BM) from BC between 2000 and 2009 at Samsung Medical Center. We analyzed TTBM from initial diagnosis of metastatic BC according to subtypes and trastzumab (T) administration before BM diagnosis. The median age of 189 BM patients from BC was 48 years. We divided TTBM into four groups considering BC subtypes and treatment; HR-positive/HER2-negative (n=45), HER2-positive with T before BM development (n=47), HER2-positive without T before BM development (n=39), and TNBC (n=58). The median TTBMs for each group were 17.5 months, 13.7 months, 5.8 months, and 2.9 months, respectively (p<0.001). HER2-positive without T (HR 1.892, p=0.008) and TNBC (HR 1.652, p=0.023) were independently associated with shorter TTBM. In multivariate analysis, HER2-positive without T (hazard ratio 1.725, p=0.002) and TNBC (hazard ratio 1.579, p=0.022) were independent risk factors for worse metastatic OS compared with HR-positive/HER2-negative subtype. TTBMs were shorter in patients with HER2-positive without T and TNBC among BC subtypes. Prospective clinical study for high risk patients for early BM is warranted.
KeywordsBreast cancer Brain metastases HER2 Triple negative Trastuzumab
Breast cancer (BC) is the second-most common cancer that spreads to the brain (Lin et al. 2004). The incidence of brain metastasis (BM) from BC appears to be increasing attributable to improved neuroimaging, increasing numbers of BC patients, and prolonged survival due to improved systemic therapies. Symptomatic BM in patients with metastatic breast cancer (MBC) occurs in 10-16% of patients, revealing up to 30% when autopsy diagnosis of BM is included (Santarelli et al. 2007; Al-Shamy & Sawaya 2009). The median survival after development of BM in BC patients is approximately 4–6 months and 1– and 2-year survival rates are approximately 20% and 2%, respectively.
Traditionally, a number of risk factors for BM from MBC have been reported to be associated with high tumor grade, a negative hormone receptor status, early-onset BC, African-American ethnicity, HER2 overexpression or the presence of lung and liver metastases. The median latency between the initial diagnosis of BC and the onset of BM is 2 to 3 years, suggesting that BM usually occurs late in the course of MBC. It has been shown by Heitz et al. (2009) triple-negative or HER2-positive BC is associated with higher and earlier BM development in the course of disease compared with ER+/HER2- subtype. However, the how BC subtypes predispose to BM differently in their longitudinal disease course and their relation with systemic treatment have not been described well.
Recently it has been reported that the tool as nomogram to predict subsequent BM in patient with MBC with non-BM (Graesslin et al. 2010). And, we have reported that new prognostic model to prediction of outcomes for patients with BM reflecting the different biologic features of BC, including treatment effect and status of extracranial disease control (Ahn et al. 2012) by refining the Sperduto’s BC-specific GPA index (Sperduto et al. 2012) through analysis of a nomogram and through the incorporation of unique biological features of BCs. Thus, we need to incorporate time to BM (TTBM) in addition to selection of enriching patients and prediction prognosis of BM from BC.
We hypothesized that MBC patients may predispose to BM differently during the disease courses according to BC subtypes and treatments, and timing of BM may affect metastatic survival.
In the present study, we aimed to describe how tumor subtype and therapy-related factors of anti-HER2 treatment differently affect TTBM in BC patients. Next, we investigated whether TTBM influence on metastatic overall survival in MBC patients.
Patients and methods
Routine screening for BM was not performed. BM was diagnosed using brain magnetic resonance imaging (MRI) and/or surgical intervention when clinically suspected. Treatment modalities for BM included symptomatic management with corticosteroids, WBRT, surgical resection, SRS, and/or systemic treatment at physician’s discretion.
Patient characteristics were compared using chi-square and Fisher’s exact test (categorical variables). Time to brain metastases (TTBM) was defined from the date of initial diagnosis of distant metastasis to the date of BM diagnosis. TTBM according to BC subtype and trastuzumab treatment was assessed by Kaplan-Meier methods and compared using log-rank test. Multivariate analysis to assess prognostic factor for TTBM was performed using a Cox-proportional hazards model, and the following factors were included in the model: age at initial diagnosis of primary BC, primary metastatic disease, initial metastatic sites including liver, lung, or bone, BC subtypes. BC subtypes were defined as follows: hormone receptor (HR)-positive type was as ER and/or PgR positive with HER2-negative, HER2-positive type wasHER2-positive irrespective of HR status, TN type was defined as lack of ER, PgR, and HER2 expressions. In addition to this, HER2-positive type was divided into two subtypes according to the treatment of trastuzumab (T): HER2-positive with T and HER2-positive without T. Metastatic overall survival (mOS) was defined from the date of initial diagnosis of distant metastases to the date of death. Metastatic OS was assessed by Kaplan-Meier method and compared using log-rank test according to BC subtypes.
Baseline characteristics of 189 breast cancer patients with brain metastases
Total N=189 (%)
Median age (range)
at initial diagnosis of distant metastasis
at initial diagnosis of BM
Menopausal status at initial diagnosis
Invasive ductal carcinoma
Invasive lobular carcinoma
Stage at initial diagnosis
HER2-positive irrespective of HR status
AntiHER2 Treatment among HER2-positive patients (N=86)
Before BM diagnosis
as an adjuvant treatment
as a neoadjuvant treatment
as a palliative treatment
After BM diagnosis
No anti-HER2 treatment
Overall Survival, median months
from initial distant metastases (mOS)
from initial BM diagnosis (BM-OS)
Characteristics of BM development according to tumor subtype
Characteristics of brain metastases according to breast cancer subtype and trastuzumab treatment before brain metastases development
Age, median (range)
At initial distant mets
At BM diagnosis
Stage at initial diagnosis
Brain as initial metastatic site
Brain,the only metastatic site
Site of initial distant metastasis
LMS‡ at BM diagnosis
ECOG PS at BM diagnosis
Number of brain metastasis
Extracranial systemic control at BM diagnosis
No other systemic mets.
Time to brain metastases (TTBM)
Cox-regression multivariate analysis of predictive factors for time to brain metastases (TTBM) from initial distant metastases
HR (95% C.I.)
Age at first diagnosis of primary disease
Stage IV at initial diagnosis of primary BC
Site of initial distant metastases
Subtype with trastuzumab effect
HER2-positive with Trastuzumab
Metastatic overall survival according to BC subtypes and trastuzuamb effect
Recent improvements of systemic treatments including new cytotoxic agents and third generation aromatase inhibitors (AI) have brought to longer survival in patients with MBC. Prominently, incorporation of targeted therapies, such as trastuzumab, in HER2-positive BC has changed the natural history of this disease, prolonging survival. Consequently, many women now survive long enough to develop CNS disease. It also has emphasized local treatment modalities, such as whole brain radiation, stereotactic surgery, and tumor removal (Chargari et al. 2010; Suh 2010; Kased et al. 2009; Muacevic et al. 2004).
With BM occurring as the result of poor systemic disease control, predicting the timing of BM development may provide rationale for early intervention and treating BM considering prognostic stratification of BM. This retrospective single-center study analyzing TTBM according to BC subtype and anti-HER2 treatment trastuzumab was based on a relatively large cohort of patients with BM from BC. The distributions of HER2-positive and TNBC among BM patients from BC were higher than in those of the general proportion of BC patients, which reflects predilection to BM of HER2-positive and TNBC BCs (Slimane et al. 2004; Sanna et al. 2007; Ryberg et al. 2005; Lin et al. 2008; Heitz et al. 2009; Pestalozzi et al. 2006). In terms of TTBM from initial diagnosis of metastatic disease, median TTBM was significantly shorter in TNBC patients (2.9 months) and HER2-positive without trastruzumab treatment (5.8 months) compared patients with HR-positive/HER2-negative (17.5 months) or HER2-positive patients who received trastuzumab (13.7 months). This propensity of HER2-positive and TNBC to early BM occurrence is consistent with previous studies by Heitz et al. (2009).This result is also supported by other translational results (Sarrio et al. 2008; Lin et al. 2004; Duchnowska et al. 2009). However, they did not investigate anti-HER2 treatment effect on TTBM. In the present study, TTBM from initial primary BC was not different according to trastuzumab treatment but TTBM from initial diagnosis of distant metastases was significantly longer in HER2-positive patients with trastuzumab treatment. In multivariate analysis, both HER2-positive without trastuzumab treatment and TNBC were independently associated with earlier BM occurrence.
Prognostic model for BM from BC patients were reported and there is biologic evidence for higher propensity for BM in HER2-positive and TNBC patients (Ahn et al. 2012; Heitz et al. 2009; Sperduto et al. 2012), although routine screening of BM for high risk patients did not show definite survival benefit (Niwinska et al. 2007).While general therapeutic nihilism should be avoided, it is still important to recognize that the number of BM, the extent of the systemic disease, and also the BC subtype have to be taken into account when choosing individual treatment regimens. Finally, special emphasis will be put on established and future approaches to prevent BM. Incorporation of TTBM to prediction of prognosis in BM from BC patients may facilitate screening at most risky period, potential development of possible prophylactic strategies, and choice of treatment modalities, which are ready for prospective clinical trial.
This study is limited in that the study population is not the entire patients with BC diagnosis, but the patients who diagnosed with BM from BC, and therefore we could not evaluate the actual incidence of BM exactly. Instead, we have evaluated the TTBM from the time of first diagnosis of metastatic BC according to subtype and targeted treatment among BM patients.
Considering high cost of screening brain MRI, the prospective clinical trial selecting the patients’ population at high risk of BM who has significant benefit from screening and treating asymptomatic BM is crucial. Given that over 50% of BM in HER2-positive and TNBC occur in the first year after diagnosis of metastatic BC in this study which is compatible with previous reports (Heitz et al. 2009), it might be reasonable to confine candidates to screen asymptomatic BM to HER2-positive and TNBC population, for more risky period after initial diagnosis of metastatic disease, and screening should be considered incorporated with systemic disease control. Moreover, in these cases of BM development with well controlled extracranial systemic disease, the optimal treatment strategy is questionable whether systemic chemotherapy regimen should be changed or maintained and how local therapy should be combined with systemic treatments, especially for patients with BM as the only progression site.
The present study identified HER2-positiveBC without trastuzumab treatment and TNBC as independent risk factors for shorter TTBM from the initial distant metastasis. Incorporating prognostic index, TTBM may provide the rational approach to plan prospective clinical trial whether there is a population in which screening at most risky period or potential prophylactic strategies for BM could have clinical benefit.
- Ahn HK, Lee S, Park YH, Sohn JH, Jo JC, Ahn JH, Jung KH, Park S, Cho EY, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kim SB, Im YH: Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. Neuro Oncol 2012.Google Scholar
- Al-Shamy G, Sawaya R: Management of brain metastases: the indispensable role of surgery. J Neurooncol 2009, 92(3):275-282. 10.1007/s11060-009-9839-yView ArticleGoogle Scholar
- Chargari C, Campana F, Pierga JY, Vedrine L, Ricard D, Le Moulec S, Fourquet A, Kirova YM: Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat Rev Clin Oncol 2010, 7(11):632-640. 10.1038/nrclinonc.2010.119View ArticleGoogle Scholar
- Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska-Mielcarek K, Karpinska A, Staroslawska E, Kubiatowski T, Szczylik C: Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009, 117(2):297-303. 10.1007/s10549-008-0275-zView ArticleGoogle Scholar
- Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK: Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 2010, 28(12):2032-2037. 10.1200/JCO.2009.24.6314View ArticleGoogle Scholar
- Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009, 45(16):2792-2798. 10.1016/j.ejca.2009.06.027View ArticleGoogle Scholar
- Kased N, Binder DK, McDermott MW, Nakamura JL, Huang K, Berger MS, Wara WM, Sneed PK: Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys 2009, 75(4):1132-1140. 10.1016/j.ijrobp.2008.12.031View ArticleGoogle Scholar
- Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 2004, 22(17):3608-3617. 10.1200/JCO.2004.01.175View ArticleGoogle Scholar
- Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP: Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008, 113(10):2638-2645. 10.1002/cncr.23930View ArticleGoogle Scholar
- Muacevic A, Kreth FW, Tonn JC, Wowra B: Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer 2004, 100(8):1705-1711. 10.1002/cncr.20167View ArticleGoogle Scholar
- Niwinska A, Tacikowska M, Pienkowski T: Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. Acta Oncol 2007, 46(7):1027-1029. 10.1080/02841860701316099View ArticleGoogle Scholar
- Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A: Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17(6):935-944. 10.1093/annonc/mdl064View ArticleGoogle Scholar
- Ryberg M, Nielsen D, Osterlind K, Andersen PK, Skovsgaard T, Dombernowsky P: Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005, 91(3):217-225. 10.1007/s10549-005-0323-xView ArticleGoogle Scholar
- Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nole F: Brain metastases in patients with advanced breast cancer. Anticancer Res 2007, 27(4C):2865-2869.Google Scholar
- Santarelli JG, Sarkissian V, Hou LC, Veeravagu A, Tse V: Molecular events of brain metastasis. Neurosurg Focus 2007, 22(3):E1.View ArticleGoogle Scholar
- Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68(4):989-997. 10.1158/0008-5472.CAN-07-2017View ArticleGoogle Scholar
- Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, Massard C, Spielmann M: Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004, 15(11):1640-1644. 10.1093/annonc/mdh432View ArticleGoogle Scholar
- Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M: Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012, 82(5):2111-2117. 10.1016/j.ijrobp.2011.02.027View ArticleGoogle Scholar
- Suh JH: Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 2010, 362(12):1119-1127. 10.1056/NEJMct0806951View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.